Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
The Category 2 designation was not a finding that BPC-157 is dangerous per se, but rather that insufficient human safety data exists to justify its use in compounded medications without the oversight of the standard drug approval process
(Spoiler: it favors Peak)
Compounded semaglutide may be a reasonable option for: Patients who do not have insurance coverage for brand-name semaglutide and do not qualify for manufacturer assistance programs Patients working with a physician who is actively monitoring them baseline metabolic labs, regular follow-up, dose adjustment based on response and tolerability Patients sourcing from a verified 503B outsourcing facility using semaglutide base (not a salt form) Patients who have been counseled on proper injection technique and the specific concentration of their formulation Patients who should be cautious: Patients using telehealth platforms that do not require baseline labs or follow-up visits a prescriber who will send semaglutide to anyone who completes an online questionnaire is not providing adequate clinical oversight Patients whose compounded formulation contains additional ingredients (B12, L-carnitine, etc.) without a clear clinical rationale for the supplements that do have evidence behind them on GLP1 therapy, and the doses that actually matter, see our GLP1 Support Protocol Patients who are self-adjusting doses without clinical guidance Patients who should avoid compounded semaglutide: Anyone sourcing from a compounder who cannot verify their 503A or 503B status and provide a Certificate of Analysis for potency and sterility testing Patients with a history of medullary thyroid carcinoma medullary thyroid carcinoma (MTC) A rare cancer of the thyroids hormone-producing C-cells
How the Wolverine Stack works The two peptides cover complementary parts of tissue repair
